A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2025.03.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Jessica Tang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Natera, Inc., Austin, TX. Hauptthemen laut MEDLINE: Kidney Transplantation, Cell-Free Nucleic Acids, Tissue Donors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natera Inc.
Abstract (Originalsprache)
BACKGROUND: Pregnant kidney transplant recipients (KTRs) are a vulnerable, high-risk population, susceptible to obstetrical complications, as well as graft rejection. Current methods used to monitor kidney transplant function lack specificity. Recently, donor derived cell-free DNA (dd-cfDNA) has emerged as a non-invasive biomarker for assessing risk for allograft rejection in KTRs. However, utilizing dd-cfDNA to monitor allograft status in pregnant KTRs requires the ability to distinguish between fetal/placental, donor, and KTR derived cfDNA. METHODS: We developed a custom bioinformatics analysis to identify and measure dd-cfDNA in 6 pregnant KTRs by sequencing maternal cfDNA (blood sample) and paternal genomic DNA (buccal swab). RESULTS: We demonstrate our ability to successfully measure dd-cfDNA in 4/6 pregnant KTRs. CONCLUSIONS: This proof-of-concept study demonstrates that dd-cfDNA can be measured in pregnant KTRs. This study lays the foundation for future research on dd-cfDNA correlations with maternal fetal conditions to help improve allograft care for this specific patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Natera, Inc., Austin, TX.
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology; David Geffen School of Medicine, University of California, Los Angeles, CA; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology; David Geffen School of Medicine, University of California, Los Angeles, CA.
- Division of Nephrology, Department of Medicine; David Geffen School of Medicine, University of California, Los Angeles, CA.
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology; David Geffen School of Medicine, University of California, Los Angeles, CA; Molecular Biology Institute, University of California, Los Angele…
Förderung
- Natera Inc
Zitieren
APA
Tang, J., Ligumsky, L. K., Woodruff, K., Jang, C., Charland, N., Al Haj Baddar, N., Ahmed, E., Van Hummelen, P., Heilek, G., Zimmermann, B., Bunnapradist, S., Tabriziani, H., & Afshar, Y. (2025). A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.03.025
Vancouver
Tang J, Ligumsky LK, Woodruff K, Jang C, Charland N, Al Haj Baddar N, et al. A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.03.025
BibTeX
@article{Tang2025,
author = {Tang, Jessica and Ligumsky, Lior Kashani and Woodruff, Kate and Jang, Christine and Charland, Nicole and Al Haj Baddar, Nour and Ahmed, Ebad and Van Hummelen, Paul and Heilek, Gabrielle and Zimmermann, Bernhard and Bunnapradist, Suphamai and Tabriziani, Hossein and Afshar, Yalda},
title = {A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2025.03.025}
}
EUVIMED